Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Operating Leases (2019 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Operating Leases for 7 consecutive years, with $95000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 94.59% year-over-year to $95000.0, compared with a TTM value of $95000.0 through Sep 2025, down 94.59%, and an annual FY2024 reading of $1.4 million, down 46.02% over the prior year.
  • Operating Leases was $95000.0 for Q3 2025 at X4 Pharmaceuticals, down from $815000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $6.5 million in Q1 2021 and bottomed at $95000.0 in Q3 2025.
  • Average Operating Leases over 5 years is $3.5 million, with a median of $3.6 million recorded in 2022.
  • The sharpest move saw Operating Leases soared 270.24% in 2021, then crashed 94.59% in 2025.
  • Year by year, Operating Leases stood at $4.8 million in 2021, then dropped by 24.56% to $3.6 million in 2022, then dropped by 27.5% to $2.6 million in 2023, then tumbled by 46.02% to $1.4 million in 2024, then tumbled by 93.26% to $95000.0 in 2025.
  • Business Quant data shows Operating Leases for XFOR at $95000.0 in Q3 2025, $815000.0 in Q2 2025, and $2.4 million in Q1 2025.